Smallpox

Researchers are observing patients diagnosed with smallpox who receive the antiviral drug tecovirimat (TPOXX). The study tracks how many patients survive at day 44 and monitors safety. Because smallpox is rare, the study relies on cases that occur naturally or in outbreaks, and i…

This Phase 3 study is testing the MVA-BN mpox vaccine in 344 infants and children aged 4 to 24 months in the Democratic Republic of the Congo, a region heavily affected by mpox. Researchers are comparing a standard dose to a half-dose to see if the lower dose is still effective a…

This Phase 3 trial is testing the safety and immune response of the MVA-BN mpox vaccine in 359 pregnant and postpartum women in the Democratic Republic of the Congo. Some women receive the vaccine during pregnancy, others right after giving birth, and a small group gets it as an …

This study tests the MVA-BN vaccine in 460 children aged 2 to 12 years, comparing their immune response and safety to adults. All participants receive two doses four weeks apart. The goal is to see if the vaccine can prevent smallpox, mpox, and related orthopoxvirus infections in…

This study looks at whether VIGIV, a blood product with antibodies, helps people who have serious reactions to the smallpox vaccine. It will track 100 patients to see if their skin lesions improve and if their antibody levels change. The goal is to confirm that VIGIV works as a t…

This study looks at whether taking the smallpox drug TPOXX changes how well the JYNNEOS vaccine works. About 100 healthy adults aged 18 to 42 will get two doses of the vaccine and either TPOXX or a placebo for 28 days. Researchers will check for side effects and measure immune re…

This study looks at how the immune system of patients in the intensive care unit (ICU) responds to severe infections caused by viruses or bacteria. Researchers will take extra blood samples from 38 adults to analyze immature granulocytes, a type of immune cell. The goal is to see…